Researchers from Princeton (N.J.) University projected what prescribing levels for buprenorphine and opioids would have been in 2020 if the pandemic had never happened, based on previous years’ prescribing data. They compared those projections to the actual prescriptions for buprenorphine and opioids between March and August of 2020.
During the time period, new prescriptions for opioids rebounded to projected levels, but new prescriptions for buprenorphine stayed low. They dropped by 18 percent of projected levels, returning to 90 percent of projected levels by August. The study found decreases in new buprenorphine prescriptions were especially common in the Northeast.
The researchers estimated that without the pandemic, as many as 36,954 people would have begun buprenorphine treatment between March and August of 2020.
“The really big picture is that it’s so hard to get effective treatment compared to how easy it is to get opioids,” Janet Currie, PhD, the study’s lead author and the head of Princeton’s Center for Health and Wellbeing, told The Philadelphia Inquirer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
